• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环磷酰胺(NSC - 26271)的选择性作用研究:组织可溶性酶对羟基化代谢物的失活作用

Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes.

作者信息

Cox P J, Phillips B J, Thomas P

出版信息

Cancer Treat Rep. 1976 Apr;60(4):321-6.

PMID:179712
Abstract

The hypothesis that selective action of cyclophosphamide, compared to other nitrogen mustards, is due to a balance between enzymatic formation of inactive metabolites and chemical formation of the alkylating product was studied in view of previous observation in our laboratory. Metabolite analysis, inhibition of growth of tumor cells in culture, and kinetic analysis of relevant enzyme activities were used in this investigation. The effect of tissue-soluble enzyme fractions on biochemically prepared aldophosphamide, aldophosphamide analogs, and phosphoramide mustard showed: (a) a range of deactivation abilities with aldophosphamide (liver greater than kidney greater than intestinal mucosa greater than tumor greater than spleen = bovine serum albumin solution); (b) the formation of different amounts of carboxyphosphamide from aldophosphamide; and (c) only comparatively small reductions in the toxicity of phosphoramide mustard and of 4-hydroxy-4methylcyclophosphamide. Correlations were found between NAD+-dependent aldehyde dehydrogenase activity and the deactivation ability of tissue-soluble enzyme fractions. Blockage (by C4 substitution) or inhibition (by disulfiram) of secondary oxidation of aldophosphamide, mediated by aldehyde dehydrogenase, resulted in diminished deactivation ability in vitro and reduced selectivity in vivo.

摘要

鉴于我们实验室之前的观察结果,对环磷酰胺与其他氮芥相比具有选择性作用的假说进行了研究,该假说认为其选择性作用归因于无活性代谢产物的酶促形成与烷基化产物的化学形成之间的平衡。本研究采用代谢物分析、培养肿瘤细胞生长抑制以及相关酶活性的动力学分析方法。组织可溶性酶组分对生化制备的醛磷酰胺、醛磷酰胺类似物和磷酰胺氮芥的作用表明:(a) 醛磷酰胺失活能力的范围(肝脏>肾脏>肠黏膜>肿瘤>脾脏 = 牛血清白蛋白溶液);(b) 醛磷酰胺形成不同量的羧基磷酰胺;(c) 磷酰胺氮芥和4-羟基-4-甲基环磷酰胺的毒性仅相对小幅降低。发现NAD⁺依赖性醛脱氢酶活性与组织可溶性酶组分的失活能力之间存在相关性。由醛脱氢酶介导的醛磷酰胺二次氧化的阻断(通过C4取代)或抑制(通过双硫仑)导致体外失活能力降低和体内选择性降低。

相似文献

1
Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes.环磷酰胺(NSC - 26271)的选择性作用研究:组织可溶性酶对羟基化代谢物的失活作用
Cancer Treat Rep. 1976 Apr;60(4):321-6.
2
The enzymatic basis of the selective action of cyclophosphamide.环磷酰胺选择性作用的酶学基础。
Cancer Res. 1975 Dec;35(12):3755-61.
3
Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.环磷酰胺(NSC-26271)相关的磷酰胺氮芥——最新进展与历史回顾
Cancer Treat Rep. 1976 Apr;60(4):337-46.
4
Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.环磷酰胺(NSC - 26271)、环磷酰胺代谢物与普通氮芥化合物的体内外比较药理学研究。
Cancer Treat Rep. 1976 Apr;60(4):301-8.
5
Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines.醛脱氢酶抑制剂对人多能及定向造血祖细胞和恶性血细胞体外对氮杂磷类药物敏感性的影响。
Cancer Res. 1987 Jun 15;47(12):3180-5.
6
Half-life of oxazaphosphorines in biological fluids.生物体液中氮杂磷三环类化合物的半衰期。
Drug Metab Dispos. 1984 Sep-Oct;12(5):553-9.
7
Identification of the mouse aldehyde dehydrogenases important in aldophosphamide detoxification.鉴定在醛磷酰胺解毒中起重要作用的小鼠醛脱氢酶。
Cancer Res. 1990 Aug 15;50(16):4991-5002.
8
Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.环磷酰胺代谢产物在大鼠肝微粒体系统及小鼠体内与DNA的结合
Cancer Res. 1985 Sep;45(9):4237-43.
9
Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.环磷酰胺通过丙烯醛和磷酰胺氮芥的联合作用调节大鼠肝脏细胞色素P450 2C11和类固醇5α-还原酶活性及信使核糖核酸水平。
Cancer Res. 1993 Jun 1;53(11):2490-7.
10
Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
Cancer Treat Rep. 1976 Apr;60(4):415-22.

引用本文的文献

1
Why Great Mitotic Inhibitors Make Poor Cancer Drugs.为什么强效有丝分裂抑制剂不能成为好的癌症药物。
Trends Cancer. 2020 Nov;6(11):924-941. doi: 10.1016/j.trecan.2020.05.010. Epub 2020 Jun 11.
2
Clinical pharmacokinetics of cyclophosphamide.环磷酰胺的临床药代动力学
Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003.
3
[Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].人体内活化环磷酰胺及其失活产物的血药浓度和尿排泄情况(作者译)
J Cancer Res Clin Oncol. 1980 Jan;96(1):79-92. doi: 10.1007/BF00412899.
4
Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study.
Cancer Chemother Pharmacol. 1984;12(3):167-72. doi: 10.1007/BF00256539.
5
Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.癌症化疗药物研发中的理念与现实,特别提及氮杂磷三环类细胞抑制剂
J Cancer Res Clin Oncol. 1986;111(1):1-12. doi: 10.1007/BF00402768.